Torsade de pointes after ziprasidone overdose with coingestants

Journal of Clinical Psychopharmacology

Volumn 30, Issue 1, 2010, Pages 76-77

  Alipour, Azita ^a   Cruz, Robyn ^b   Lott, Rex S ^c  

^a KAISER PERMANENTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c IDAHO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; CIPROFLOXACIN; FLUCONAZOLE; FLUOXETINE; TRAZODONE; ZIPRASIDONE;

ADULT; ALCOHOL CONSUMPTION; CASE REPORT; CLINICAL FEATURE; DRUG OVERDOSE; ELECTROCARDIOGRAM; FEMALE; HUMAN; LABORATORY TEST; LETTER; PRIORITY JOURNAL; QT PROLONGATION; SUICIDE ATTEMPT; TORSADE DES POINTES;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; FEMALE; HUMANS; LONG QT SYNDROME; MIDDLE AGED; OVERDOSE; PIPERAZINES; THIAZOLES; TORSADES DE POINTES;

EID: 74549178506     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181c914d3     Document Type: Letter

References (20)

1. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008;65:1029-1038.
2. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs. 2003;17:423-430.
3. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47: 264-268.
4. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia and sudden death. J Clin Psychopharmacol. 2003;23:58-77.
5. Reilly JG, Ayls SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048-1052.
6. Kelly DL, Love RC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacol Bull. 2001;35:66-79.
7. Burton S, Heslop K, Harrison K, et al. Ziprasidone overdose. Am J Psychiatry. 2000;157:835.
8. Harrigan EP, Micelli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62-69.
9. Manini AF, Raspberry D, Hoffman R, et al. QT prolongation and torsades de pointes following overdose of ziprasidone and amantadine. J Med Toxicol. 2007; 3:178-181.
10. Jaffe R, Leavitt R, Wind T. QTc prolongation in multiple drug overdose. J Clin Psychopharmacol. 2004;24:348-349.
11. LoVecchio F, Watts D, Eckholdt P. Three-year experience with ziprasidone exposures. Am J Emerg Med. 2005;23: 586-587.
12. Arbuck D. 12,800-mg ziprasidone overdose without significant ECG changes. Gen Hosp Psychiatry. 2005;27:222.
13. House M. Overdose of ziprasidone. Am J Psychiatry. 2002;159:1061-1062.
14. Gomez-Criado MS, Bernardo M, de Florez T, et al. Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review. Pharmacotherapy. 2005; 25:1660-1665.
15. Stollberger S, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005;20:243-251.
16. Justo D, Prokhorov V, Heller K, et al. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand. 2005;111:171-176.
17. Schenck JB, Rizvi AA, Lin T. Severe primary hypothyroidism manifesting with torsades de pointes. Am J Med Sci. 2006;331:154-156.
18. Burgess CD, Hames TK, George CF. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur J Clin Pharmacol. 1982;23:417-421.
19. Everson G, Lasseter KC, Anderson KE, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br J Clin Pharmacol. 2000; 49(suppl 1):21S-26S.
20. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.